Theratechnologies Hires Vice President, Human Resources
May 31 2021 - 8:00AM
Theratechnologies Inc. (Theratechnologies, or the Company (TSX: TH)
(NASDAQ: THTX)), a biopharmaceutical company focused on the
development and commercialization of innovative therapies, is
pleased to announce that Mr. André Dupras is joining the Company as
Vice President, Human Resources.
“André brings crucial expertise and capabilities
at a time when the Company needs to attract and retain the best
talent required to grow our commercial assets and pursue the
development of our research pipeline,” said Paul Lévesque,
President and Chief Executive Officer, Theratechnologies.
“As demand for talented and experienced
resources is high, André will play a pivotal role in giving
Theratechnologies the edge to continue building a strong team and
bringing new capabilities. On behalf of the entire team at
Theratechnologies, I want to extend my warmest welcome to our new
colleague,” added Mr. Lévesque.
Mr. Dupras brings more than 25 years of
experience in Human Resources. Most recently, he was Vice President
of Human Resources at Clementia Pharmaceuticals. Previously, he
spent 15 years at Pfizer Canada in various leadership roles in
Human Resources and in Commercialization. He also worked at
Bombardier Aerospace in Global Compensation, Aon Hewitt and
Réno-Dépôt. Mr. Dupras holds a Master’s in Management Science –
Human Resources and a Bachelor’s in Administration (Marketing and
Human Resources), both from HEC Montreal. He is a member of the
Order of Certified Human Resources Professionals. He will report
directly to the President and Chief Executive Officer of
Theratechnologies, Mr. Paul Lévesque, and will be based in
Montreal, Canada.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical
company focused on the development and commercialization of
innovative therapies addressing unmet medical needs. Further
information about Theratechnologies is available on the Company's
website at www.theratech.com, on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking statements and
forward-looking information, or, collectively, forward-looking
statements, within the meaning of applicable securities laws, that
are based on our management’s beliefs and assumptions and on
information currently available to our management. You can identify
forward-looking statements by terms such as "may", "will",
"should", "could", “would”, "outlook", "believe", "plan",
"envisage", "anticipate", "expect" and "estimate", or the negatives
of these terms, or variations of them. The forward-looking
statements contained in this press release include, but are not
limited to, statements regarding the growth of Theratechnologies
and the development of its pipeline.
Forward-looking statements are based upon a
number of assumptions and include, but are not limited to, the
following: sales of our products in the United States will increase
over time, our products will not be subject to recalls, no unknown
side effects will be discovered from the long-term use of our
products, our products will continue to be reimbursed by
third-party payors, pre-clinical in vivo results obtained with
TH1902 will be replicated in humans during the ongoing Phase 1
clinical trial, treatment with TH1902 will be efficacious and safe
in various types of cancer, we will be able to enroll patients to
complete our Phase 1 clinical trial using TH1902, we will meet our
announced timelines, including those related to the beginning of
our Phase 3 clinical trial using tesamorelin for the potential
treatment of NASH in the general population and we will have the
funds necessary to carry out our business plan.
Forward-looking statements are subject to a
variety of risks and uncertainties, many of which are beyond our
control that could cause our actual results to differ materially
from those that are disclosed in or implied by the forward-looking
statements contained in this press release. These risks and
uncertainties include, among others, the risk that the current
Covid-19 pandemic forces us to adversely amend our previously
announced timelines because, among other factors, of safety
measures implemented in the United States and in Europe, employees’
illness and shortage of products or materials, that the sales of
our products decrease over time, that we are subject to product
recalls, that adverse safety issues are discovered from the
long-term use of our products, that we are found to be in violation
of laws and regulation governing the commercialization of products
resulting in the payment of fines or other penalties, that our
intellectual property on our products is challenged and found to be
invalid, that we are unable to replicate pre-clinical in vivo
results obtained with TH1902 when administered into humans, that we
are unable to enroll patients for our clinical trials and that we
do not have the funds necessary to carry out our business plan.
We refer potential investors to the "Risk
Factors" section of our annual information form dated February 24,
2021 available on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov as an exhibit to our report on Form 40-F dated February
25, 2021 under Theratechnologies’ public filings for additional
risks regarding the conduct of our business and Theratechnologies.
The reader is cautioned to consider these and other risks and
uncertainties carefully and not to put undue reliance on
forward-looking statements. Forward-looking statements reflect
current expectations regarding future events and speak only as of
the date of this press release and represent our expectations as of
that date.
We undertake no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise, except as may be required by applicable law.
For media inquiries:Denis BoucherVice President,
Communications and Corporate
Affairs514-336-7800communications@theratech.com
For investor inquiries:Leah GibsonSenior
Director, Investor Relations617-356-1009ir@theratech.com
Theratechnologies (NASDAQ:THTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theratechnologies (NASDAQ:THTX)
Historical Stock Chart
From Apr 2023 to Apr 2024